Comparative Efficacy and the Muscarinic Breakthrough: A Comprehensive Network Meta-Analysis of Antipsychotic Interventions for Acute Schizophrenia
Posted innews Psychiatry

Comparative Efficacy and the Muscarinic Breakthrough: A Comprehensive Network Meta-Analysis of Antipsychotic Interventions for Acute Schizophrenia

This landmark network meta-analysis of 438 RCTs evaluates 24 antipsychotics, revealing clozapine as the most effective while highlighting the novel muscarinic agonist xanomeline-trospium. The study emphasizes clinically relevant efficacy differences and a shifting tolerability landscape, advocating for more individualized, evidence-based treatment strategies in acute schizophrenia management.
Beyond Dopamine Blocking: Network Meta-Analysis Redefines Efficacy and Tolerability Hierarchies in Acute Schizophrenia
Posted innews Psychiatry

Beyond Dopamine Blocking: Network Meta-Analysis Redefines Efficacy and Tolerability Hierarchies in Acute Schizophrenia

A landmark network meta- **Developing Article Components** I'm now diving deep into the content, focusing on fleshing out each section. The Highlight section's first drafts are complete. I'm incorporating the study's key findings on drug efficacy rankings, and the unique safety profile of Xanomeline-Trospium. I'm simultaneously drafting the study design, and drafting the background section, and I am ensuring a clear comparison of the two, while keeping the technical details accurate. analysis of 438 RCTs reveals significant efficacy differences among antipsychotics and highlights the unique clinical profile of the first-in-class muscarinic agonist, xanomeline-trospium, relative to traditional antidopaminergic agents.
Semaglutide Mitigates Cardiometabolic Risk in Early-Stage Schizophrenia: Insights from a Randomized Clinical Trial
Posted inDiabetes & Endocrinology news Psychiatry

Semaglutide Mitigates Cardiometabolic Risk in Early-Stage Schizophrenia: Insights from a Randomized Clinical Trial

A landmark RCT demonstrates that adjunctive semaglutide significantly improves glycemic control and induces substantial weight loss in individuals with schizophrenia spectrum disorders treated with second-generation antipsychotics, potentially closing the mortality gap in this high-risk population.
Psychosocial Interventions for Dual-Diagnosis Schizophrenia: A Critical Appraisal of Efficacy and the Urgent Need for Innovation
Posted innews Psychiatry

Psychosocial Interventions for Dual-Diagnosis Schizophrenia: A Critical Appraisal of Efficacy and the Urgent Need for Innovation

A comprehensive meta-analysis in JAMA Psychiatry reveals that current psychosocial interventions for schizophrenia and co-occurring substance use disorders offer negligible impact on symptoms and no significant effect on substance use reduction, with the notable exception of nicotine cessation strategies.
Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS
Posted innews Psychiatry

Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS

Three multinational phase 3 trials found no clinically meaningful cognitive benefit of the GlyT1 inhibitor iclepertin versus placebo in schizophrenia, though the drug was well tolerated. Results highlight methodological and biological challenges in developing treatments for cognitive impairment associated with schizophrenia.
Theta Burst Stimulation of the Temporo-Parietal Cortex for Persistent Auditory Hallucinations in Schizophrenia: A Comprehensive Review of a Phase 3 Randomised Multicentre Trial and Contextual Evidence
Posted inClinical Updates news Psychiatry

Theta Burst Stimulation of the Temporo-Parietal Cortex for Persistent Auditory Hallucinations in Schizophrenia: A Comprehensive Review of a Phase 3 Randomised Multicentre Trial and Contextual Evidence

This review synthesizes evidence on bilateral continuous theta burst stimulation (cTBS) of the temporo-parietal cortex for persistent auditory verbal hallucinations (AVH) in schizophrenia, focusing on a landmark German phase 3 trial demonstrating safety and modest efficacy.